Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CompumedicsASX:CMP +2.27%55 Price-to-Tangible-Book is 8.65 as of Aug. 01, 2026, which is 72% above its 10-year median of 5.04. GuruFocus rates ASX:CMP with a GF Score™ of 55/100 and a GF Value™ of A$0.32 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 700 Medical Devices & Instruments companies, Compumedics ranks worse than 81.86% on this metric.
As of today (2026-08-01), Compumedics's share price is A$0.225. Compumedics's Tangible Book per Share of Dec. 2025 for the quarter that ended in Dec. 2025 was A$0.03. Hence, Compumedics's Price to Tangible Book Ratio of today is 8.65.
The historical rank and industry rank for Compumedics's Price-to-Tangible-Book or its related term are showing as below:
ASX:CMP'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.6 Med: 5.04 Max: 12.88
Current: 7.5
During the past 13 years, Compumedics's highest Price to Tangible Book Ratio was 12.88. The lowest was 1.60. And the median was 5.04.
ASX:CMP's Price-to-Tangible-Book is ranked worse than 81.86% of 700
companies
in the Medical Devices & Instruments industry
Industry Median: 2.5
vs ASX:CMP: 7.50
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Compumedics Price-to-Tangible-Book Related Terms
Compumedics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Compumedics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMP vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Compumedics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Compumedics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Compumedics (ASX:CMP) has a Price-to-Tangible-Book of 8.65 as of Aug. 01, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Compumedics and its competitors. This is 72% above median its historical median of 5.04. Over the past decade, Compumedics' Price-to-Tangible-Book has ranged from 1.60 to 12.88. According to the industry distribution chart, Compumedics ranks #573 out of 700 companies in the Medical Devices & Instruments industry, placing it in the top 81.9%.
Is Compumedics' Price-to-Tangible-Book too high?
Compumedics' current Price-to-Tangible-Book of 8.65 is 72% above median its 10-year median of 5.04. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 12.88. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.50. Compumedics' value of 8.65 is 246% above this industry median. Based on the distribution chart, Compumedics ranks #573 out of 700 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Compumedics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #573 out of 700 companies for Price-to-Tangible-Book. This places Compumedics in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.50. Compumedics' value of 8.65 is 246% above this benchmark. Historically, Compumedics' own Price-to-Tangible-Book has ranged from 1.60 to 12.88 over the past decade. While the company's 10-year median is 5.04 vs. the industry median of 2.50, Compumedics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.50, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current Price-to-Tangible-Book of 8.65 is 246% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current Price-to-Tangible-Book is 8.65, which is 72% above median its own 10-year median of 5.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.32, compared to a current price of A$0.23 — trading 29.7% below its estimated fair value. The current Price-to-Tangible-Book is 8.65, which is 72% above median its 10-year median of 5.04 and 246% above the Medical Devices & Instruments industry median of 2.50. Compumedics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Price-to-Tangible-Book is 8.65 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.23 is trading 29.7% below its estimated GF Value™ of A$0.32.
GuruFocus considers Compumedics to be Possible Value Trap.
Key valuation signals for ASX:CMP:
Price-to-Tangible-Book: 8.65 (72% above median its 10-year median of 5.04)
GF Value™: A$0.32 vs. price of A$0.23 (29.7% below fair value)
Industry Position: 246% above the Medical Devices & Instruments median (#573 of 700)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
55GF Score
Get the complete analysis for ASX:CMP
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
